436 related articles for article (PubMed ID: 32531207)
1. Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity.
Zhu H; Blum RH; Bernareggi D; Ask EH; Wu Z; Hoel HJ; Meng Z; Wu C; Guan KL; Malmberg KJ; Kaufman DS
Cell Stem Cell; 2020 Aug; 27(2):224-237.e6. PubMed ID: 32531207
[TBL] [Abstract][Full Text] [Related]
2. Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity.
Bernard PL; Delconte R; Pastor S; Laletin V; Costa Da Silva C; Goubard A; Josselin E; Castellano R; Krug A; Vernerey J; Devillier R; Olive D; Verhoeyen E; Vivier E; Huntington ND; Nunes J; Guittard G
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35589278
[TBL] [Abstract][Full Text] [Related]
3. CIS is a potent checkpoint in NK cell-mediated tumor immunity.
Delconte RB; Kolesnik TB; Dagley LF; Rautela J; Shi W; Putz EM; Stannard K; Zhang JG; Teh C; Firth M; Ushiki T; Andoniou CE; Degli-Esposti MA; Sharp PP; Sanvitale CE; Infusini G; Liau NP; Linossi EM; Burns CJ; Carotta S; Gray DH; Seillet C; Hutchinson DS; Belz GT; Webb AI; Alexander WS; Li SS; Bullock AN; Babon JJ; Smyth MJ; Nicholson SE; Huntington ND
Nat Immunol; 2016 Jul; 17(7):816-24. PubMed ID: 27213690
[TBL] [Abstract][Full Text] [Related]
4. Harnessing features of adaptive NK cells to generate iPSC-derived NK cells for enhanced immunotherapy.
Woan KV; Kim H; Bjordahl R; Davis ZB; Gaidarova S; Goulding J; Hancock B; Mahmood S; Abujarour R; Wang H; Tuininga K; Zhang B; Wu CY; Kodal B; Khaw M; Bendzick L; Rogers P; Ge MQ; Bonello G; Meza M; Felices M; Huffman J; Dailey T; Lee TT; Walcheck B; Malmberg KJ; Blazar BR; Bryceson YT; Valamehr B; Miller JS; Cichocki F
Cell Stem Cell; 2021 Dec; 28(12):2062-2075.e5. PubMed ID: 34525347
[TBL] [Abstract][Full Text] [Related]
5. NK Cell Priming From Endogenous Homeostatic Signals Is Modulated by CIS.
Delconte RB; Guittard G; Goh W; Hediyeh-Zadeh S; Hennessy RJ; Rautela J; Davis MJ; Souza-Fonseca-Guimaraes F; Nunès JA; Huntington ND
Front Immunol; 2020; 11():75. PubMed ID: 32082327
[TBL] [Abstract][Full Text] [Related]
6. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.
Li Y; Hermanson DL; Moriarity BS; Kaufman DS
Cell Stem Cell; 2018 Aug; 23(2):181-192.e5. PubMed ID: 30082067
[TBL] [Abstract][Full Text] [Related]
7. Leveraging CD16 fusion receptors to remodel the immune response for enhancing anti-tumor immunotherapy in iPSC-derived NK cells.
Meng F; Zhang S; Xie J; Zhou Y; Wu Q; Lu B; Zhou S; Zhao X; Li Y
J Hematol Oncol; 2023 Jun; 16(1):62. PubMed ID: 37316891
[TBL] [Abstract][Full Text] [Related]
8. ADSC secretome constrains NK cell activity by attenuating IL-2-mediated JAK-STAT and AKT signaling pathway via upregulation of CIS and DUSP4.
Ko E; Yoon T; Lee Y; Kim J; Park YB
Stem Cell Res Ther; 2023 Nov; 14(1):329. PubMed ID: 37964351
[TBL] [Abstract][Full Text] [Related]
9. Induced Pluripotent Stem Cell-conditioned Medium Suppressed Melanoma Tumorigenicity Through the Enhancement of Natural-Killer Cellular Immunity.
Hsieh CT; Luo YH; Chien CS; Wu CH; Tseng PC; Chiou SH; Lee YC; Whang-Peng J; Chen YM
J Immunother; 2016 May; 39(4):153-9. PubMed ID: 27023059
[TBL] [Abstract][Full Text] [Related]
10. IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.
Mao Y; van Hoef V; Zhang X; Wennerberg E; Lorent J; Witt K; Masvidal L; Liang S; Murray S; Larsson O; Kiessling R; Lundqvist A
Blood; 2016 Sep; 128(11):1475-89. PubMed ID: 27465917
[TBL] [Abstract][Full Text] [Related]
11. Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer.
Hermanson DL; Bendzick L; Pribyl L; McCullar V; Vogel RI; Miller JS; Geller MA; Kaufman DS
Stem Cells; 2016 Jan; 34(1):93-101. PubMed ID: 26503833
[TBL] [Abstract][Full Text] [Related]
12. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
[TBL] [Abstract][Full Text] [Related]
13. Umbilical Cord Blood and iPSC-Derived Natural Killer Cells Demonstrate Key Differences in Cytotoxic Activity and KIR Profiles.
Goldenson BH; Zhu H; Wang YM; Heragu N; Bernareggi D; Ruiz-Cisneros A; Bahena A; Ask EH; Hoel HJ; Malmberg KJ; Kaufman DS
Front Immunol; 2020; 11():561553. PubMed ID: 33178188
[TBL] [Abstract][Full Text] [Related]
14. Anti-NKG2C/IL-15/anti-CD33 killer engager directs primary and iPSC-derived NKG2C
Chiu E; Felices M; Cichocki F; Davis Z; Wang H; Tuninga K; Vallera DA; Lee T; Bjordahl R; Malmberg KJ; Valamehr B; Miller JS
Mol Ther; 2021 Dec; 29(12):3410-3421. PubMed ID: 34174441
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum- and feeder-free conditions.
Lupo KB; Moon JI; Chambers AM; Matosevic S
Cytotherapy; 2021 Oct; 23(10):939-952. PubMed ID: 34272175
[TBL] [Abstract][Full Text] [Related]
16. Expression of CISH, an Inhibitor of NK Cell Function, Increases in Association with Ovarian Cancer Development and Progression.
Acosta JC; Bahr JM; Basu S; O'Donnell JT; Barua A
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830840
[TBL] [Abstract][Full Text] [Related]
17. Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells.
Gurney M; O'Reilly E; Corcoran S; Brophy S; Krawczyk J; Otto NM; Hermanson DL; Childs RW; Szegezdi E; O'Dwyer ME
Cytotherapy; 2022 Nov; 24(11):1087-1094. PubMed ID: 36050244
[TBL] [Abstract][Full Text] [Related]
18. iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting.
Goldenson BH; Hor P; Kaufman DS
Front Immunol; 2022; 13():841107. PubMed ID: 35185932
[TBL] [Abstract][Full Text] [Related]
19. Disruption of CISH promotes the antitumor activity of human T cells and decreases PD-1 expression levels.
Lv J; Qin L; Zhao R; Wu D; Wu Z; Zheng D; Li S; Luo M; Wu Q; Long Y; Tang Z; Tang YL; Luo X; Yao Y; Yang LH; Li P
Mol Ther Oncolytics; 2023 Mar; 28():46-58. PubMed ID: 36654786
[TBL] [Abstract][Full Text] [Related]
20. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
